PROVECTUS BIOPHARMACEUTICALS, INC. financial data

Symbol
PVCT on OTC
Location
Knoxville, TN
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 10% % -21%
Debt-to-equity -112% % 2.4%
Return On Equity 115% % 165%
Return On Assets -943% % -226%
Operating Margin -1345% % -259%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 420,279,879 shares 0%
Common Stock, Shares, Outstanding 420,279,879 shares 0%
Entity Public Float $51,633,218 USD 13%
Common Stock, Value, Issued $420,280 USD 0%
Weighted Average Number of Shares Outstanding, Basic 420,279,879 shares 0.09%
Weighted Average Number of Shares Outstanding, Diluted 420,279,879 shares 0.09%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $460,185 USD -33%
Research and Development Expense $2,158,694 USD 16%
General and Administrative Expense $4,700,559 USD 182%
Operating Income (Loss) $6,508,813 USD -132%
Nonoperating Income (Expense) $229,753 USD -15%
Net Income (Loss) Attributable to Parent $6,633,120 USD -119%
Earnings Per Share, Basic 0 USD/shares 0%
Earnings Per Share, Diluted 0 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $72,479 USD -61%
Other Assets, Current $90,844 USD
Assets, Current $277,988 USD -63%
Property, Plant and Equipment, Net $3,465 USD -35%
Operating Lease, Right-of-Use Asset $138,451 USD 277%
Assets $419,904 USD -48%
Accounts Payable, Current $1,177,776 USD -15%
Employee-related Liabilities, Current $310,000 USD
Liabilities, Current $6,471,656 USD 4%
Operating Lease, Liability, Noncurrent $91,637 USD
Liabilities $6,586,914 USD 5.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax $60,327 USD -0.21%
Retained Earnings (Accumulated Deficit) $261,688,770 USD -2.6%
Stockholders' Equity Attributable to Parent $6,150,832 USD -13%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $6,167,010 USD -14%
Liabilities and Equity $419,904 USD -48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,093,444 USD -4.7%
Net Cash Provided by (Used in) Financing Activities $1,073,115 USD 37%
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 420,279,879 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $20,272 USD 92%
Deferred Tax Assets, Valuation Allowance $47,012,636 USD -0.7%
Deferred Tax Assets, Gross $47,076,089 USD -0.76%
Operating Lease, Liability $138,789 USD 268%
Depreciation $467 USD -79%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $6,684,327 USD -119%
Lessee, Operating Lease, Liability, to be Paid $148,948 USD 287%
Operating Lease, Liability, Current $47,152 USD 25%
Lessee, Operating Lease, Liability, to be Paid, Year Two $25,669 USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One $12,835 USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 40%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $10,159 USD 1186%
Deferred Tax Assets, Operating Loss Carryforwards $41,456,195 USD -1%
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Operating Lease, Payments $12,571 USD 8.1%
Additional Paid in Capital $255,163,053 USD 2.4%
Share-based Payment Arrangement, Expense $1,281,326 USD -67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%